BIOMAT Database Logo BIOMAT Database Logo

Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas. 1990

O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Service of Endocrinology, Research Center Notre-Dame Hospital, University of Montreal, Canada.

CV 205-502, a new long-acting nonergot dopamine agonist, was given to 15 patients (6 women and 9 men) with PRL-secreting pituitary macroadenomas. The compound was administered in a single daily dose for a period of 6-12 months. The treatment resulted in normalization of plasma PRL levels (less than or equal to 20 micrograms/L) in 5 of 6 women at a mean dose of 135 micrograms (range, 75-300 micrograms) and in 6 of 9 men at a mean dose of 192 micrograms (range, 75-300 micrograms). Among patients for whom computed tomographic scans were available before and after at least 6 months of therapy, definite tumor shrinkage occurred in 6 of 7 patients. Libido was improved in 5 of 6 women and in 6 of 8 men, galactorrhea disappeared in all cases (3 women and 1 man) and menses resumed in 3 of 5 women. Plasma testosterone rose to normal levels in 3 of 6 men who were not receiving testosterone injections. The PRL response to TRH was blunted in 4 of 6 patients with normalized basal PRL. Serum total cholesterol was reduced by CV 205-502 treatment in women from 5.35 +/- 0.49 to 4.63 +/- 0.51 mmol/L (P = 0.031) and in men from 5.93 +/- 0.89 to 5.28 +/- 0.82 mmol/L (P = 0.045). Side-effects included mainly headache, nausea, and dizziness. One side-effect or more occurred transiently and with mild intensity in 14 patients. No patient discontinued the therapy because of side-effects. In conclusion, CV 205-502 appears to be a safe and valuable compound in the treatment of patients with PRL-secreting macroadenomas.

UI MeSH Term Description Entries
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
May 1990, Annals of internal medicine,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Long-term treatment of macroprolactinomas with CV 205-502.
April 1993, Acta endocrinologica,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
June 1994, The Journal of reproductive medicine,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Long-term treatment of prolactin-secreting macroadenomas with pergolide.
January 2000, The Journal of clinical endocrinology and metabolism,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.
February 1992, Clinical endocrinology,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas.
September 2003, European journal of endocrinology,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
CV 205-502 treatment of hyperprolactinemia.
February 1989, The Journal of clinical endocrinology and metabolism,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
CV 205-502 treatment of macroprolactinomas.
October 1991, Journal of endocrinological investigation,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
CV 205-502 treatment in therapy-resistant acromegalic patients.
May 1995, European journal of endocrinology,
O Serri, and H Beauregard, and J Lesage, and L Pedneault, and R Comtois, and N Jilwan, and M Somma, and L Vachon, and J Brownell
Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
July 1995, Clinical endocrinology,
Copied contents to your clipboard!